TITLE

Anti-ganglioside antibodies induced in chickens by an alum-adsorbed anti-idiotype antibody targeting NeuGcGM3

AUTHOR(S)
Guthmann, Marcelo D.; Venier, Cecilia; Toledo, Darien; Segatori, Valeria I.; Alonso, Daniel F.; Fainboim, Leonardo; Vázquez, Ana M.; Ostrowski, Hector
PUB. DATE
January 2013
SOURCE
Frontiers in Immunology;Jan2013, Vol. 4, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Racotumomab is a murine anti-idiotype cancer vaccine targeting NeuGcGM3 on melanoma, breast, and lung cancer. In order to characterize the immunogenicity of alum-adsorbed racotumomab in a non-clinical setting, Leghorn chickens were immunized in dose levels ranging from 25 μg to 1600μg. Racotumomab was administered subcutaneously in the birds' neck with three identical boosters and serum samples were collected before, during and after the immunization schedule. A strong antibody response was obtained across the evaluated dose range, confirming the immunogenicity of racotumomab even at dose levels as low as 25 μg. As previously observed when using Freund's adjuvant, alum-adsorbed racotumomab induced an idiotype-specific response in all the immunized birds and ganglioside-specific antibodies in 60-100% of the animals. In contrast to the rapid induction anti-idiotype response, detection of ganglioside-specific antibodies in responsive animals may require repeated boosting. Kinetics of anti-NeuGcGM3 antibody titers showed a slight decline 2 weeks after each booster, arguing in favor of repeated immunizations in order to maintain antibody titer. Interestingly, the intensity of the anti-NeuGcGM3 response paralleled that of anti-mucin antibodies and anti-tumor antibodies, suggesting that the in vitro detection of anti-ganglioside antibodies might be a surrogate for an in vivo activity of racotumomab. Taken together, these results suggest that Leghorn chicken immunization might become the means to test the biological activity of racotumomab intended for clinical use.
ACCESSION #
88043791

 

Related Articles

  • EVALUATION OF HUMORAL IMMUNE RESPONSE TO NEUGCGM3/VSSP VACCINE IN METASTATIC MELANOMA PATIENTS. Torrella, A.; Noris, E.; González, A.; Arango, M del C.; Rodríguez, B.; Osorio, M.; Anasagasti, L.; Rodriguez, E.; Mon, R.; Carr, A.; Fernández, L. E. // Revista VacciMonitor (Vacunología y Temas Afines);Oct2002, Vol. 11 Issue 4, p1 

    Introduction: Melanoma has become a promising target for active immunotherapy. In the Center of Molecular Immunology of Cuba was development an ganglioside cancer vaccine (NeuGcGM3/VSSP/ Montanide ISA 51). Material and Methods: This vaccine was tested in a phase Ib clinical trial in stage IV...

  • Impact of minimal tumor burden on antibody response to vaccination. Kim, Soo-Kie; Wu, Xiaohong; Ragupathi, Govind; Gathuru, John; Koide, Fusataka; Cheung, Nai-Kong; Panageas, Katherine; Livingston, Philip // Cancer Immunology, Immunotherapy;May2011, Vol. 60 Issue 5, p621 

    Four randomized phase III trials conducted recently in melanoma patients in the adjuvant setting have been based in part on the correlation between antibody responses in immunized patients and improved survival. Each of these randomized trials demonstrated no clinical benefit, although again...

  • Melanoma vaccines: Are we making any progress? Wen-Jen Hwu // Hem/Onc Today;8/25/2008, Vol. 9 Issue 15, p3 

    The author assesses the progress made by the U.S. in developing vaccines for melanoma. She cites several reasons why melanoma is being used as a model to develop cancer vaccine therapy, one of which is the rare long-lasting tumor regression with immunotherapy. The author points out that the...

  • Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8+ T cells-mediated protection against melanoma B16 challenge. Mazorra, Zaima; Mesa, Circe; Fernández, Audry; Fernández, Luis E. // Cancer Immunology, Immunotherapy;Dec2008, Vol. 57 Issue 12, p1771 

    Preventive immunotherapy is an attractive strategy for patients at a high risk of having cancer. The success of prophylactic cancer vaccines would depend on the selection of target antigens that are essential for tumour growth and progression. The overexpression of GM3 ganglioside in murine and...

  • Immunotherapy in advanced cutaneous melanoma patients. Mackiewicz, Jacek; Krokowicz, Łukasz // Menopausal Review / Przeglad Menopauzalny;2013, Vol. 12 Issue 5, p429 

    The incidence of cancer has been increasing worldwide. Melanoma is known to be one of the most immunogenic malignancies in humans. In recent years innovative and promising therapeutic strategies that modulate the immune response or target various intracellular pathways in melanoma have been...

  • Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model. Ruf, Peter; Sch„fer, Beatrix; Eissler, Nina; Mocikat, Ralph; Hess, Juergen; Pl”scher, Matthias; Wosch, Susanne; Suckstorff, Ivonne; Zehetmeier, Christine; Lindhofer, Horst // Journal of Translational Medicine;2012, Vol. 10 Issue 1, p219 

    Background: Trifunctional bispecific antibodies (trAb) are a special class of bispecific molecules recruiting and activating T cells and accessory immune cells simultaneously at the targeted tumor. The new trAb Ektomab that targets the melanoma-associated ganglioside antigen GD2 and the...

  • Therapeutic Vaccines for Melanoma. Faries, Mark B.; Morton, Donald L. // BioDrugs;2005, Vol. 19 Issue 4, p247 

    Considerable clinical research is focused on improving systemic treatments for melanoma. Unfortunately, the disease is generally resistant to standard chemotherapy, and surgical excision remains the best treatment option whenever possible. However, complete spontaneous regression of melanoma has...

  • Adjuvant vaccine ineffective in melanoma. Sondak, Vernon K. // Hem/Onc Today;6/25/2008, Vol. 9 Issue 11, p3 

    The article discusses research being done on the effect of adjuvant vaccine for the treatment of stage II melanoma. It references a study by Alexander M. Eggermont presented at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Eggermont reported that...

  • Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside. Basak, Saroj; Birebent, Brigitte; Purev, Enkhtsetseg; Somasundaram, Rajasekharan; Maruyama, Haruhiko; Zaloudik, Jan; Swoboda, Rolf; Strittmatter, Wolfgang; Li, Weiping; Luckenbach, Albrecht; Song, Hong; Li, Jian; Sproesser, Katrin; Guerry, Dupont; Nair, Sridar; Furukawa, Koichi; Herlyn, Dorothee // Cancer Immunology, Immunotherapy;Mar2003, Vol. 52 Issue 3, p145 

    Gangliosides are potentially useful targets for tumor destruction by antibodies. However, the role of gangliosides in T cell-mediated immunity to tumors is unclear. We produced three murine monoclonal anti-idiotypic antibodies (Ab2) against a monoclonal antibody (Ab1) that binds strongly to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics